East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Sitagliptin + Metformin
Janumet
Not routinely available
SMC (492/08)
29/03/2023

Indication

Type 2 diabetes. SMC restriction: restricted to use in patients for whom a combination of sitagliptin and metformin is an appropriate choice of therapy and only when the addition of sulphonylureas to metformin monotherapy is not appropriate. Sitagliptin represents an alternative to other agents such...

Type 2 diabetes. SMC restriction: restricted to use in patients for whom a combination of sitagliptin and metformin is an appropriate choice of therapy and only when the addition of sulphonylureas to metformin monotherapy is not appropriate. Sitagliptin represents an alternative to other agents such as thiazolidinediones.

Therapeutic Area

Endocrine system

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

50mg and metformin hydrochloride 1000mg tablets

Comments

-

Link to Advice

492/08

Advice Published

10/05/2010

SMC Submission Type

Abbreviated

SMC Status

Restricted